Aciclovir is NOT recommended for routine treatment of hand, foot, and mouth disease in children
There is no established evidence-based dosing regimen for aciclovir in pediatric hand, foot, and mouth disease (HFMD), and its use is not supported by current guidelines or FDA approval for this indication. HFMD is caused by enteroviruses (primarily Coxsackievirus A16 and Enterovirus A71), not herpesviruses, and aciclovir has no established mechanism of action against these pathogens 1.
Why Aciclovir Should Not Be Used
The available evidence does not support aciclovir for HFMD:
Mechanism mismatch: Aciclovir is specifically designed to target herpesvirus thymidine kinase 2. Enteroviruses causing HFMD lack this enzyme entirely, making the theoretical basis for efficacy implausible 2.
Anecdotal reports only: The published literature consists solely of isolated case reports 2, 3, 4, 5 with no controlled trials, no pediatric dosing studies, and no demonstration of efficacy beyond temporal association. One 1996 case series suggested benefit but acknowledged the lack of biological plausibility 2.
No guideline support: None of the comprehensive pediatric infectious disease guidelines 6 recommend aciclovir for HFMD. These guidelines extensively cover aciclovir dosing for herpesvirus infections but make no mention of enteroviral diseases.
Standard Management Approach
HFMD management is supportive in the vast majority of cases 7, 8:
- Symptomatic relief: Acetaminophen or ibuprofen for fever and pain
- Hydration: Oral fluids; cold liquids may be better tolerated with oral lesions
- Soft diet: Avoid acidic, spicy, or rough-textured foods that irritate oral ulcers
- Observation: Monitor for warning signs of severe disease
When to Escalate Care
Hospitalization and intensive supportive care are indicated for severe/complicated HFMD 7, 8:
- Neurological signs: altered mental status, seizures, ataxia, myoclonus, cranial nerve palsies
- Cardiopulmonary compromise: tachycardia out of proportion to fever, tachypnea, pulmonary edema, shock
- Persistent high fever with lethargy
- Inability to maintain hydration
For severe cases, intravenous immunoglobulin (IVIG) has been recommended by several guideline committees 7, though specific dosing protocols vary by institution. This represents the only intervention with some evidence base beyond supportive care.
Critical Caveat
The one exception where aciclovir might be considered is in immunocompromised patients with prolonged, severe HFMD 3. A case report documented resolution in an immunosuppressed adult with metastatic cancer after 3.5 weeks of persistent disease, using aciclovir 200 mg five times daily 3. However, this remains off-label, unproven, and should only be attempted after consultation with pediatric infectious disease specialists.
Prevention Focus
Given the lack of effective antiviral therapy, prevention is paramount 8, 9:
- Hand hygiene with soap and water (alcohol-based sanitizers are less effective against enteroviruses)
- Disinfection of contaminated surfaces with bleach-based cleaners
- Exclusion from childcare until fever resolves and lesions crust over
- Inactivated EV-A71 vaccines (available in China, showing >90% efficacy) 8
The bottom line: Do not prescribe aciclovir for routine pediatric HFMD. The disease is self-limited in 7-10 days in immunocompetent children 7. Focus on symptomatic management and vigilant monitoring for the rare severe complications requiring hospitalization.